CRISPR Therapeutics AG (CRSP) Equity Average (2016 - 2026)

CRISPR Therapeutics AG has disclosed Equity Average across 11 years of filings, most recently posting $1.9 billion for Q1 2026.

• Equity Average for Q1 2026 came in at $1.9 billion, down 0.66% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.9 billion (down 0.66% YoY), and the FY2025 annual result was $1.9 billion, up 1.02% from the prior year.
• Equity Average came in at $1.9 billion for Q1 2026 at CRISPR Therapeutics AG, down from $1.9 billion in the prior quarter.
• In the past five years, Equity Average ranged from a high of $2.3 billion in Q1 2022 to a low of $1.8 billion in Q2 2025.
• The 5-year median for Equity Average is $1.9 billion (2022), against an average of $1.9 billion.
• Peak annual rise in Equity Average reached 33.85% in 2022, while the deepest fall reached 22.05% in 2022.
• CRISPR Therapeutics AG's Equity Average stood at $1.9 billion in 2022, then declined by 5.71% to $1.8 billion in 2023, then increased by 7.23% to $1.9 billion in 2024, then declined by 0.88% to $1.9 billion in 2025, then dropped by 2.64% to $1.9 billion in 2026.
• The last three Equity Average figures came in at $1.9 billion (Q1 2026), $1.9 billion (Q4 2025), and $1.8 billion (Q3 2025), per Business Quant data.